Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Using the CYP3A Activity Evaluation to Predict the Efficacy and Safety of Diazepam in Patients With Alcohol Withdrawal Syndrome.
J Pharm Pract. 2022 Aug;35(4):518-523. doi: 10.1177/0897190021997000. Epub 2021 Feb 24.
J Pharm Pract. 2022.
PMID: 33622083
Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome.
Skryabin VY, Zastrozhin M, Torrado M, Grishina E, Ryzhikova K, Shipitsyn V, Galaktionova T, Sorokin A, Bryun E, Sychev D.
Skryabin VY, et al.
Hosp Pharm. 2021 Oct;56(5):592-596. doi: 10.1177/0018578720931756. Epub 2020 Jun 2.
Hosp Pharm. 2021.
PMID: 34720165
Free PMC article.
Item in Clipboard
Effects of CYP2C19*17 genetic polymorphisms on plasma and saliva concentrations of diazepam in patients with alcohol withdrawal syndrome.
Skryabin VY, Zastrozhin M, Torrado M, Grishina E, Ryzhikova K, Shipitsyn V, Galaktionova T, Bryun E, Sychev D.
Skryabin VY, et al.
Psychiatr Genet. 2022 Apr 1;32(2):67-73. doi: 10.1097/YPG.0000000000000306.
Psychiatr Genet. 2022.
PMID: 35001019
Item in Clipboard
How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?
Skryabin VY, Zastrozhin MS, Torrado MV, Grishina EA, Ryzhikova KA, Shipitsyn VV, Galaktionova TE, Sorokin AS, Bryun EA, Sychev DA.
Skryabin VY, et al. Among authors: galaktionova te.
Drug Metab Pers Ther. 2020 Mar 5;35(1):/j/dmdi.2020.35.issue-1/dmpt-2019-0026/dmpt-2019-0026.xml. doi: 10.1515/dmpt-2019-0026.
Drug Metab Pers Ther. 2020.
PMID: 32134726
Item in Clipboard
Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.
Zastrozhin MS, Sorokin AS, Agibalova TV, Grishina EA, Antonenko AР, Rozochkin IN, Duzhev DV, Skryabin VY, Galaktionova TE, Barna IV, Orlova AV, Aguzarov AD, Savchenko LM, Bryun EA, Sychev DA.
Zastrozhin MS, et al. Among authors: galaktionova te.
Hum Psychopharmacol. 2018 Nov;33(6):e2677. doi: 10.1002/hup.2677. Epub 2018 Oct 25.
Hum Psychopharmacol. 2018.
PMID: 30357930
Item in Clipboard
Cite
Cite